AVNR

Avanir Pharmaceuticals, Inc. Press Releases

$11.79
*  
0.11
0.94%
Get AVNR Alerts
*Delayed - data as of Oct. 21, 2014  -  Find a broker to begin trading AVNR now
Exchange: NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save stocks for next time
Viewing
Filtered By
Ordered By
Avanir Pharmaceuticals Announces Presentation of AVP-923 Phase II Results in Agitation in Patients with Alzheimer's Disease at the American Neurological Association Meeting
10/13/2014 4:26:00 PM - PR Newswire
▼-0.08 % Price Change since this news event. The Volume Ratio is 2.02.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Avanir Pharmaceuticals to Host Investor Briefing on October 15, 2014
10/8/2014 4:15:00 PM - PR Newswire
▲0.43 % Price Change since this news event. The Volume Ratio is 0.54.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Avanir Pharmaceuticals Announces Data Presentations at the American Neurological Association's (ANA) 2014 Annual Meeting Including Results from the Phase II Trial for Treatment of Agitation in Patients with Alzheimer's Disease
10/8/2014 8:30:00 AM - PR Newswire


Avanir Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
9/29/2014 9:15:00 AM - PR Newswire


Avanir Pharmaceuticals Announces Pricing of Public Offering of Common Stock
9/23/2014 10:00:00 PM - PR Newswire


Avanir Pharmaceuticals Announces Proposed Public Offering of Common Stock
9/22/2014 4:45:00 PM - PR Newswire


Avanir Pharmaceuticals Announces Positive Phase II Trial Results for AVP-923 in Treatment of Agitation in Patients with Alzheimer's Disease
9/15/2014 8:30:00 AM - PR Newswire


Avanir Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Conference
9/2/2014 9:00:00 AM - PR Newswire


Avanir Pharmaceuticals Announces Initiation of Phase II Study of AVP-786 for the Adjunctive Treatment of Major Depressive Disorder
8/26/2014 9:00:00 AM - PR Newswire


Avanir Pharmaceuticals Reports Fiscal 2014 Third Quarter Financial and Business Update
8/5/2014 4:01:00 PM - PR Newswire


Avanir Pharmaceuticals to Participate in Two Conferences in August
8/5/2014 8:30:00 AM - PR Newswire


Avanir Pharmaceuticals Announces Date of Fiscal 2014 Third Quarter Financial Results and Conference Call
7/28/2014 8:30:00 AM - GlobeNewswire